title: Mutagenic assessment of olmesartan cilexetil by bacterial mutation assay.
abstract: Hypertension is a serious health problem due to high frequency and concomitant other diseases including cardiovascular and renal dysfunction. Olmesartan cilexetil is a new antihypertensive drug associated with angiotensin II receptor antagonist. This study was conducted to evaluate the mutagenicity of olmesartan cilexetil by bacterial reverse mutation test using Salmonella typhimurium (TA100, TA1535, TA98, and TA1537) and Escherichia coli (WP2 uvrA). At the concentrations of 0, 62, 185, 556, 1667, and 5000 μg/ plate, olmesartan cilexetil was negative in both Salmonella typhimurium and Escherichia coli regardless of presence or absence of metabolic activation system (S9 mix). These results demonstrate that olmesartan cilexetil does not induce bacterial reverse mutation.
authors.affiliation: Department of Pharmacology, CKD Research Institute, Yongin, Korea.
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Kim
authors.affiliation: Toxicological Screening and Testing Division, National Institute of Food and Drug Safety Evaluation, Osong, Korea.
authors.forename: Ilyoung
authors.initials: I
authors.lastname: Ahn
authors.affiliation: College of Pharmacy, Dankook University, Cheonan, Korea.
authors.forename: Sung Ha
authors.initials: SH
authors.lastname: Ryu
authors.affiliation: CTC BIO Inc. Paltan, Hwaseong, Korea.
authors.forename: Hong Ryeol
authors.initials: HR
authors.lastname: Jeon
authors.affiliation: CTC BIO Inc. Paltan, Hwaseong, Korea.
authors.forename: Bong Sang
authors.initials: BS
authors.lastname: Lee
authors.affiliation: College of Pharmacy, Dankook University, Cheonan, Korea.
authors.forename: Kyu-Bong
authors.initials: KB
authors.lastname: Kim
keywords: Angiotension II receptor antagonist; Hypertension; Mutagenicity; Olmesartan cilexetil